Serum levels of tenascin-C variants in congestive heart failure patients: Comparative analysis of ischemic, dilated, and hypertensive cardiomyopathy

Clinical Laboratory

Volumn 60, Issue 6, 2014, Pages 1007-1013

  Franz, Marcus ^a   Berndt, Alexander ^a   Grün, Katja ^a   Kuethe, Friedhelm ^a   Fritzenwanger, Michael ^a   Figulla, Hans Reiner ^a   Jung, Christian ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Dilated cardiomyopathy; Extra cellular matrix remodeling; Heart failure; Hypertension; Ischemic cardiomyopathy; Tenascin C

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; TENASCIN;

ADULT; ARTICLE; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FUNCTION TEST; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HUMAN; HYPERTENSION; HYPERTENSIVE CARDIOMYOPATHY; ISCHEMIC CARDIOMYOPATHY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; TENASCIN;

EID: 84903768219     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.130702     Document Type: Article

References (30)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:948-54.
2. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. The Medical Journal of Australia 2011;194:405-9.
3. Veazie PJ, Noyes K, Li Q, et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. Journal of the American College of Cardiology 2012;60:-1940-4.
4. Motiwala SR, Januzzi JL, Jr. Using Biomarkers to "Guide" Heart Failure Management: Current Perspectives and Future Directions. Cardiology in Review 2012;21(3):127-34.
5. Rybak JN, Trachsel E, Scheuermann J, Neri D. Ligand-based vascular targeting of disease. Chem Med Chem 2007;2:22-40.
6. Bowers SL, Banerjee I, Baudino TA. The extracellular matrix: at the center of it all. Journal of Molecular and Cellular Cardiology 2010;48:474-82.
7. Schwarzbauer JE. Fibronectin: from gene to protein. Current opinion in cell biology 1991;3:786-91. (Pubitemid 121006134)
8. Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. The Journal of Biological Chemistry 1995;270:6243-5.
9. Gabler U, Berndt A, Kosmehl H, et al. Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants. Heart 1996;75:358-62. (Pubitemid 26155567)
10. Imanaka-Yoshida K, Matsumoto K, Hara M, Sakakura T, Yoshida T. The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation 2003;71:291-8. (Pubitemid 36819114)
11. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histology and Histopathology 2004;19:517-25. (Pubitemid 38443913)
12. Franz M, Berndt A, Altendorf-Hofmann A, et al. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. European Journal of Heart Failure 2009;11:1057-62.
13. Franz M, Brehm BR, Richter P, et al. Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C C variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies. Journal of Molecular Histology 2010;41:39-50.
14. Baldinger A, Brehm BR, Richter P, et al. Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis. Histochemistry and Cell Biology 2011;135:427-41.
15. Franz M, Neri D, Berndt A. Chronic cardiac allograft rejection: critical role of ED-A(+) fibronectin and implications for targeted therapy strategies. The Journal of Pathology 2012;226:557-61.
16. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. The Journal of Pathology 1996;179:321-5. (Pubitemid 26266413)
17. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, et al. Tenascin-C is a useful marker for disease activity in myocarditis. The Journal of Pathology 2002;197:388-94. (Pubitemid 34778310)
18. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. The American Journal of Pathology 2005;167:-71-80.
19. Aso N, Tamura A, Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. The American Journal of Cardiology 2004;94:1468-70. (Pubitemid 39556230)
20. Terasaki F, Okamoto H, Onishi K, et al. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007;71:327-30. (Pubitemid 46409533)
21. Niebroj-Dobosz I, Madej-Pilarczyk A, Marchel M, Sokolowska B, Hausmanowa-Petrusewicz I. Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy. Clinica Chimica Acta 2011;412:-1533-1538.
22. Fujimoto N, Onishi K, Sato A, et al. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. Journal of Cardiac Failure 2009;15:898-905.
23. Schumann C, Lepper PM, Frank H, et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers 2010;15:523-32.
24. Celik A, Kocyigit I, Calapkorur B, et al. Tenascin-C may be a predictor of acute pulmonary thromboembolism. Journal of Atherosclerosis and Thrombosis 2011;18:487-93.
25. Siri A, Knauper V, Veirana N, Caocci F, Murphy G, Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. The Journal of Biological Chemistry 1995;270:8650-4.
26. Golledge J, Clancy P, Maguire J, Lincz L, Koblar S. The role of tenascin C in cardiovascular disease. Cardiovascular Research 2011;92:19-28.
27. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. The Journal of Pathology 2005;205:460-7. (Pubitemid 40361334)
28. Hessel MH, Bleeker GB, Bax JJ, et al. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. European Journal of Heart Failure 2007;9:-1058-63.
29. Sarli B, Topsakal R, Kaya EG, Akpek M, Lam YY, Kaya MG. Tenascin-C as Predictor of Left Ventricular Remodeling and Mortality in Patients With Dilated Cardiomyopathy. J Investig Med 2013 Apr;61(4):728-32.
30. Bielecka-Dabrowa A, von Haehling S, Aronow WS, Ahmed MI, Rysz J, Banach M. Heart failure biomarkers in patients with dilated cardiomyopathy. Int J Cardiol 2013 Feb 14 [Epub ahead of print].